tetano
Editor, Senior Moderator
Virulence
. 2023 Mar 13;2190650.
doi: 10.1080/21505594.2023.2190650. Online ahead of print.
An important call: suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications
Li-Jane Shih[SUP] 1 2 [/SUP], Chun-Chun Yang[SUP] 3 [/SUP], Min-Tser Liao[SUP] 4 5 [/SUP], Kuo-Cheng Lu[SUP] 6 [/SUP], Wan-Chung Hu[SUP] 7 [/SUP], Chih-Pei Lin[SUP] 3 7 [/SUP]
Affiliations
Abstract
The global coronavirus disease 2019 (COVID-19) pandemic has a detrimental impact on public health. COVID-19 usually manifests as pneumonia, which can progress into acute respiratory distress syndrome (ARDS) related to uncontrolled TH17 immune reaction. Currently, there is no effective therapeutic agent to manage COVID-19 with complications. The currently available anti-viral drug remdesivir has an effectiveness of 30% in SARS-CoV-2-induced severe complications. Thus, there is a need to identify effective agents to treat COVID-19 and the associated acute lung injury and other complications. The host immunological pathway against this virus typically involves the THαβ immune response. THαβ immunity is triggered by type 1 interferon and interleukin-27 (IL-27), and the main effector cells of the THαβ immune response are IL10-CD4 T cells, CD8 T cells, NK cells, and IgG1-producing B cells. In particular, IL-10 exerts a potent immunomodulatory or anti-inflammatory effect and is an anti-fibrotic agent for pulmonary fibrosis. Concurrently, IL-10 can ameliorate acute lung injury or ARDS, especially those caused by viruses. Owing to its anti-viral activity and anti-pro-inflammatory effects, in this review, IL-10 is suggested as a possible treatment agent for COVID-19.
Keywords: ARDS; COVID-19; IL-10; Tr1; virus.
. 2023 Mar 13;2190650.
doi: 10.1080/21505594.2023.2190650. Online ahead of print.
An important call: suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications
Li-Jane Shih[SUP] 1 2 [/SUP], Chun-Chun Yang[SUP] 3 [/SUP], Min-Tser Liao[SUP] 4 5 [/SUP], Kuo-Cheng Lu[SUP] 6 [/SUP], Wan-Chung Hu[SUP] 7 [/SUP], Chih-Pei Lin[SUP] 3 7 [/SUP]
Affiliations
- PMID: 36914565
- DOI: 10.1080/21505594.2023.2190650
Abstract
The global coronavirus disease 2019 (COVID-19) pandemic has a detrimental impact on public health. COVID-19 usually manifests as pneumonia, which can progress into acute respiratory distress syndrome (ARDS) related to uncontrolled TH17 immune reaction. Currently, there is no effective therapeutic agent to manage COVID-19 with complications. The currently available anti-viral drug remdesivir has an effectiveness of 30% in SARS-CoV-2-induced severe complications. Thus, there is a need to identify effective agents to treat COVID-19 and the associated acute lung injury and other complications. The host immunological pathway against this virus typically involves the THαβ immune response. THαβ immunity is triggered by type 1 interferon and interleukin-27 (IL-27), and the main effector cells of the THαβ immune response are IL10-CD4 T cells, CD8 T cells, NK cells, and IgG1-producing B cells. In particular, IL-10 exerts a potent immunomodulatory or anti-inflammatory effect and is an anti-fibrotic agent for pulmonary fibrosis. Concurrently, IL-10 can ameliorate acute lung injury or ARDS, especially those caused by viruses. Owing to its anti-viral activity and anti-pro-inflammatory effects, in this review, IL-10 is suggested as a possible treatment agent for COVID-19.
Keywords: ARDS; COVID-19; IL-10; Tr1; virus.